Secukinumab

Secukinumab may slow structural ankylosing spondylitis progression

LONDON – Long-term treatment with the interleukin 17A inhibitor secukinumab showed suggestive evidence of inhibiting structural progression of spinal disease…
www.rheumatologynews.com|By MITCHEL L. ZOLER

This is a big deal, coz even the anti-TNFs have not demonstrated the ability to prevent structural progression like ankyloses.

Secukinumab found ineffective in treating Crohn’s disease, possibly worsening it even

Anti-interleukin-17A monoclonal antibody secukinumab did not effectively treat patients with Crohn’s disease and was associated with higher rates of adverse events in a recent study. In a double blind, placebo-controlled proof-of-concept trial, 59 patients with moderate-to-severe Crohn’s…
healio.com
gut.bmj.com

Secukinumab Study Focuses on Inflammatory Bowel Disease

EULAR 2016: Inflammatory bowel disease is commonly associated with psoriasis, psoriatic…
www.rheumatologynetwork.com

No Increased Risk of Colitis Flares in Secukinumab Trials

©JuanGaertner/Shutterstock.com

No increased incidence of inflammatory bowel disease has been seen among patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis treated with…
rheumnow.com